Last reviewed · How we verify
Converthera NAD plus Patch (NAD+)
At a glance
| Generic name | NAD+ |
|---|---|
| Also known as | nicotinamide adenine dinucleotide (NAD+) |
| Sponsor | Through Medical INC. |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
Common side effects
- Glucose increased
- Instillation site discharge
- Triglycerides increased
- Fatigue
- Bladder spasm
- Micturition urgency
- Hematuria
- Creatinine increased
- Pyrexia
- Chills
- Dysuria
- Phosphate decreased
Serious adverse events
- Coronary artery disease
- Hematuria
- Acute coronary syndrome
- Atrial fibrillation
- Syncope
- Dehydration
- Hypoglycemia
- Heart failure
- Pericarditis
- Sepsis
Key clinical trials
- Multi-System Analysis of Opioid Receptor Binding (PHASE1)
- Shared Decision Making for Antipsychotic Medications (NA)
- Brain NAD in Alzheimer's Disease
- A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors (PHASE1,PHASE2)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- NAD Supplementation and Vascular Health in PAD (PHASE1,PHASE2)
- NAD+ Oral Supplement Pilot Intervention in Adult Females (NA)
- NAD+ and Exercise in FA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Converthera NAD plus Patch CI brief — competitive landscape report
- Converthera NAD plus Patch updates RSS · CI watch RSS
- Through Medical INC. portfolio CI